Readoutin 135d
Vertex Pharmaceuticals Incorporated — ELX/TEZ/IVA
Phase 3 primary completion: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Cystic Fibrosis